Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Other Operating Expenses for 7 years, with the latest figure at $96.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 50.62% year-over-year to $96.4 million; the trailing twelve-month figure through Mar 2026 stood at $341.9 million (up 54.15% YoY), and the FY2025 full-year result was $307.2 million, up 62.36% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $96.4 million, up from $91.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $96.4 million in Q1 2026, with the low at $8.7 million in Q2 2022.
• Historically, Other Operating Expenses has averaged $43.1 million across 5 years, with a median of $31.4 million in 2024.
• Annual changes were most pronounced in 2022 — Other Operating Expenses jumped 317.78% — and 2023, when it advanced 22.86%.
• Kiniksa Pharmaceuticals International's Other Operating Expenses stood at $14.2 million in 2022, then surged by 86.36% to $26.5 million in 2023, then surged by 149.16% to $66.1 million in 2024, then soared by 37.66% to $91.0 million in 2025, then climbed by 5.93% to $96.4 million in 2026.
• The last three Other Operating Expenses figures came in at $96.4 million (Q1 2026), $91.0 million (Q4 2025), and $83.6 million (Q3 2025), per Business Quant data.